Literature DB >> 21836461

Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats.

Torbjörn U C Järbe1, Hongfen Deng, Subramanian K Vadivel, Alexandros Makriyannis.   

Abstract

We examined four different cannabinergic aminoalkylindole ligands, including one drug (AM678=JWH018) found in herbal 'Spice' concoctions, for their ability to substitute for Δ(9)-tetrahydrocannabinol (THC), and the ability of the cannabinoid receptor 1-selective antagonist/inverse agonist rimonabant to block the substitution, 30 and 90 min after intraperitoneal injection. Rats trained to discriminate the effects of vehicle from those produced by 3 mg/kg of THC were used. The order of potency was: AM5983AM678>AM2233>WIN55212-2 at both test intervals. AM5983 and AM678 appeared eight times more potent than THC, followed by AM2233 (about twice as potent as THC), and WIN55212-2 approximately THC at the 30-min test interval. The aminoalkylindoles showed reduced potency (i.e. an increased ED50 value) at the longer injection-to-test interval of 90 min compared with testing at 30 min. The rightward shifts by coadministration of rimonabant were approximately 8-fold to 12-fold for AM5983 and AM678, compared with an approximately 3-fold rightward shift for the WIN55212-2 curve. AM2233 (1.8 mg/kg) substitution was also blocked by 1 mg/kg of rimonabant. In conclusion, AM5983 and AM678=JWH018 are potent cannabimimetics derived from an aminoalkylindole template. WIN55212-2 seemed to interact differently with rimonabant, compared with either AM5983 or AM678, indicating potential differences in the mechanism(s) of action among cannabinergic aminoalkylindoles.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21836461      PMCID: PMC3212432          DOI: 10.1097/FBP.0b013e328349fbd5

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  38 in total

1.  Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist.

Authors:  Jean De Vry; Klaus Rüdiger Jentzsch
Journal:  Eur J Pharmacol       Date:  2002-12-20       Impact factor: 4.432

2.  Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.

Authors:  Lance R McMahon
Journal:  J Pharmacol Exp Ther       Date:  2006-08-30       Impact factor: 4.030

3.  Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.

Authors:  Lance R McMahon; Brett C Ginsburg; R J Lamb
Journal:  Psychopharmacology (Berl)       Date:  2007-08-03       Impact factor: 4.530

Review 4.  Indoles and related compounds as cannabinoid ligands.

Authors:  Clementina Manera; Tiziano Tuccinardi; Adriano Martinelli
Journal:  Mini Rev Med Chem       Date:  2008-04       Impact factor: 3.862

Review 5.  Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities.

Authors:  Barbara Bosier; Giulio G Muccioli; Emmanuel Hermans; Didier M Lambert
Journal:  Biochem Pharmacol       Date:  2010-03-03       Impact factor: 5.858

6.  Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.

Authors:  Jennifer L Stewart; Lance R McMahon
Journal:  J Pharmacol Exp Ther       Date:  2010-04-07       Impact factor: 4.030

7.  Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A.

Authors:  A. Pério; M. Rinaldi-Carmona; J. Maruani; F. Barth; G. Le Fur; P. Soubrié
Journal:  Behav Pharmacol       Date:  1996-01       Impact factor: 2.293

8.  Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233.

Authors:  Jasbeer Dhawan; Hongfeng Deng; S John Gatley; Alexandros Makriyannis; Tolulope Akinfeleye; Magalie Bruneus; Alexis A Dimaio; Andrew N Gifford
Journal:  Synapse       Date:  2006-08       Impact factor: 2.562

9.  Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol.

Authors:  D R Compton; L H Gold; S J Ward; R L Balster; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1992-12       Impact factor: 4.030

10.  Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats.

Authors:  J L Wiley; R L Barrett; J Lowe; R L Balster; B R Martin
Journal:  Neuropharmacology       Date:  1995-06       Impact factor: 5.250

View more
  30 in total

1.  A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors.

Authors:  Kathryn A Seely; Lisa K Brents; Anna Radominska-Pandya; Gregory W Endres; Gregory S Keyes; Jeffery H Moran; Paul L Prather
Journal:  Chem Res Toxicol       Date:  2012-03-15       Impact factor: 3.739

2.  Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Authors:  Lisa K Brents; Anna Gallus-Zawada; Anna Radominska-Pandya; Tamara Vasiljevik; Thomas E Prisinzano; William E Fantegrossi; Jeffery H Moran; Paul L Prather
Journal:  Biochem Pharmacol       Date:  2012-01-18       Impact factor: 5.858

3.  Inhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in mice.

Authors:  Jason M Wiebelhaus; Justin L Poklis; Alphonse Poklis; Robert E Vann; Aron H Lichtman; Laura E Wise
Journal:  Drug Alcohol Depend       Date:  2012-07-07       Impact factor: 4.492

4.  Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-06-01

5.  Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Authors:  Brian F Thomas; Timothy W Lefever; Ricardo A Cortes; Megan Grabenauer; Alexander L Kovach; Anderson O Cox; Purvi R Patel; Gerald T Pollard; Julie A Marusich; Richard C Kevin; Thomas F Gamage; Jenny L Wiley
Journal:  J Pharmacol Exp Ther       Date:  2017-01-13       Impact factor: 4.030

Review 6.  Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

Authors:  Kathryn A Seely; Jeff Lapoint; Jeffery H Moran; Liana Fattore
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-26       Impact factor: 5.067

Review 7.  "Herbal incense": designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays.

Authors:  Torbjörn U C Järbe; Roger S Gifford
Journal:  Life Sci       Date:  2013-07-25       Impact factor: 5.037

8.  Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.

Authors:  Jenny L Wiley; Julie A Marusich; Timothy W Lefever; Megan Grabenauer; Katherine N Moore; Brian F Thomas
Journal:  Neuropharmacology       Date:  2013-08-02       Impact factor: 5.250

9.  Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats.

Authors:  Torbjörn U C Järbe; Brian J LeMay; Aneetha Halikhedkar; JodiAnne Wood; Subramanian K Vadivel; Alexander Zvonok; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2013-09-05       Impact factor: 4.530

Review 10.  Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Authors:  William E Fantegrossi; Jeffery H Moran; Anna Radominska-Pandya; Paul L Prather
Journal:  Life Sci       Date:  2013-09-29       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.